comparemela.com

Latest Breaking News On - National major new product plan - Page 1 : comparemela.com

Luoxin Pharmaceutical s LX-039 (Innovative Anti-Tumor Drug): Phase I Clinical Study Data Presented at ESMO 2023

/PRNewswire/ From October 20 to 24, the 2023 ESMO Congress was held in Madrid, Spain. LX-039, an innovative anti-tumor drug developed by Luoxin.

Luoxin pharmaNational torch planLuoxin pharmaceutical group stock co ltdClinical cancer researchTechnology innovation model enterpriseFudan university shanghai cancer centerNational major new product planChinese pharmaceutical enterprisesNational industrial quality model enterpriseLuoxin pharmaceuticals group stock co ltdLuoxin pharmaceuticalProfessor hu xichunFudan university shanghai cancerLouxin pharmaceuticalCancer researchPharmaceutical enterprises

Luoxin Pharmaceutical signs licensing agreement with Austria-based Marinomed Biotech AG for Budesolv® Budesonide Nasal Spray

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Hong kongMacau generalShandong luoxinBryan liuAndreas grassauerChinese pharmaceutical enterprisesNational major new product planMain board of the vienna stock exchangeNational torch planInternational forum of allergy rhinologyNational industrial quality model enterpriseTechnology innovation model enterpriseLuoxin pharmaceutical group stock co ltdAustria based marinomed biotechBudesonide nasalLuoxin pharmaceutical

vimarsana © 2020. All Rights Reserved.